Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 20/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 20/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 20/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 20/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29623586 | 1.00 | PDE4A (0.52) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL30543740 | 0.99 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL154624 | 0.99 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7380391 | 0.93 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7378596 | 0.90 | PDE4A (0.48) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7209404 | 0.90 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL6154541 | 0.90 | PDE4A (0.50) | PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL7379329 | 0.90 | PDE4B (0.41) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL7205722 | 0.90 | PDE4A (0.42) | PDE4APDE4BPDE4CPDE4D | |
| Hydrochloric Acid SCHEMBL7023896 | 0.89 | PDE4A (0.49) | PDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 448 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180318271-A1 | Use of PDE4 Inhibitors for the Prophylaxis and/or Therapy of Dyslipoproteinaemia and Related Disorders | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2018-11-08 | — | — | US | claimed |
| EP-2828242-B1 | NOVEL POLYMORPHIC CRYSTAL FORMS OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-(R)-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE, HEMINAPADISYLATE AS AGONIST OF THE ß2 ADRENERGIC RECEPTOR. | ALMIRALL SA (ES) | 2017-10-04 | — | — | EP | claimed |
| WO-2017080919-A1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | ALBERT-LUDWIGS-UNIVERSITÄT FREIBURG (DE) | 2017-05-18 | — | — | WO | claimed |
| EP-3165224-A1 | USE OF PDE4 INHIBITORS FOR THE PROPHYLAXIS AND/OR THERAPY OF DYSLIPOPROTEINAEMIA AND RELATED DISORDERS | Albert-Ludwigs-Universität Freiburg (DE) | 2017-05-10 | — | — | EP | claimed |
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2015-04-30 | — | — | US | claimed |
| EP-2804603-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2014-11-26 | — | — | EP | claimed |
| WO-2013106547-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-07-18 | — | — | WO | claimed |
| EP-2311818-B1 | Combination of a 5-phenylthiazole compound as PI3 kinase inhibitor with an antiinflammatory, bronchodilatory or antihistamine drug | NOVARTIS AG (CH) | 2013-01-16 | — | — | EP | claimed |
| EP-2121615-B1 | NAPADISYLATE SALT OF 5-(2-{[6-(2,2-DIFLUORO-2-PHENYLETHOXY)HEXYL]AMINO}-1-HYDROXYETHYL)-8-HYDROXYQUINOLIN-2(1H)-ONE AS AGONIST OF THE BETA 2 ADRENERGIC RECEPTOR | ALMIRALL SA (ES) | 2012-03-28 | — | — | EP | claimed |
| US-7803760-B2 | Methods of inducing ovulation | MERCK SERONO SA (CH) | 2010-09-28 | — | — | US | claimed |
| US-5939422-A | AN ENZYME INHIBITOR AS BRONCHODILATOR, RELAXANTS, ANTIINFLAMMATORY AGENT FOR TREATING ASTHMA, ALLERGIES, INFLAMMATION, DEPRESSION, DEMENTIA, DISEASES ASSOCIATED WITH ABNORMAL HIGH LEVEL OF CYTOKINE | EURO-CELTIQUE, S.A. (LU) | 1999-08-17 | — | — | US | claimed |
| EP-0705265-B1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | EURO CELTIQUE SA (LU) | 1999-07-28 | — | — | EP | claimed |
| EP-0916673-A1 | 6-Amino purine derivatives having PDE-IV inhibition activity | Euroceltique S.A. (LU) | 1999-05-19 | — | — | EP | claimed |
| EP-0912575-A1 | IMPROVED METHODS FOR THE SYNTHESIS OF CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITORY ACTIVITY | Euro-Celtique S.A. (LU) | 1999-05-06 | — | — | EP | claimed |
| US-5864037-A | Methods for the synthesis of chemical compounds having PDE-IV inhibitory activity | EURO-CELTIQUE, S.A. (LU) | 1999-01-26 | — | — | US | claimed |
| WO-1997046561-A1 | IMPROVED METHODS FOR THE SYNTHESIS OF CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITORY ACTIVITY | EURO-CELTIQUE, S.A. (LU) | 1997-12-11 | — | — | WO | claimed |
| JP-H09500376-A | — | — | 1997-01-14 | — | — | JP | claimed |
| CN-1125445-A | Novel compounds having P.DE-IV inhibitory activity | EURO CELTIQUE SA (LU) | 1996-06-26 | — | — | CN | claimed |
| EP-0705265-A1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | Euroceltique S.A. (LU) | 1996-04-10 | — | — | EP | claimed |
| WO-1995000516-A1 | NOVEL CHEMICAL COMPOUNDS HAVING PDE-IV INHIBITION ACTIVITY | EURO-CELTIQUE S.A. (LU) | 1995-01-05 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150119399-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | IAPP, GPR119, PCNA | PDE4A 1173/4885PDE4B 1204/4885PDE4C 1042/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.